Moon Eun-Sang – CEO, SillaJen – South Korea
SillaJen’s CEO shares his passion for his companies oncolytic vaccinia virus, and its potential to revolutionize the treatment of solid tumor cancers, even arguing that it may eventually constitute ‘a…
SillaJen, Inc. is a privately-held biotechnology company focusing on engineering and developing best-in-class oncolytic immunotherapeutics. SillaJen has Korean offices in Busan (R&D), at Pusan National University (PNU), and in Seoul (finance, management & legal). SillaJen also has Clinical R&D, regulatory affairs and CMC capabilities in San Francisco, California, one of the world’s leading biotechnology centers and the “birthplace” of the biotech industry. SillaJen products are engineered from vaccinia which has unique attributes as an oncolytic immunotherapy.
Contact Details
Busan Office
Seoul Office
San Francisco Office
SillaJen’s CEO shares his passion for his companies oncolytic vaccinia virus, and its potential to revolutionize the treatment of solid tumor cancers, even arguing that it may eventually constitute ‘a…
After a long career at leading diagnostics companies in research and business development roles, Young Kuk Yun decided to use his accumulated experience to start a venture dedicated to providing…
Two leading executive recruitment specialists – DHR International’s Helen Park and Egon Zehnder’s Eugene Kim – outline the qualities they look for when hiring pharma country managers for the challenging…
Steve Hong, CEO, and Tony Lim, vice president & COO of Lemon Healthcare, lift the lid on the new streamlined hospital data services they are offering, and the benefits to…
The French-Korean Chamber of Commerce and Industry (FKCCI) has grown rapidly in the last decade, both in terms of members and revenues. Its managing director, Stella Yoon, explains how the…
YongBum Choi, general manager of Ferring Korea, explains how he plans to foster the Ferring values in the local affiliate. Mr Choi also breaks down the stigmas associated with assisted…
The Pharmaceutical Strategy Institute (PSI) is a Korean consulting firm helping local biotech companies reach success by providing strategic and legal counsel all along the value chain. Its founder &…
James Jungkue Lee, founder and CEO of Bridge Biotherapeutics, explains his strategy for risk mitigation in running a virtual biotech start-up. He also offers his insights into the company’s partnership…
Dr Jin Hyoung Kang, president of the Cancer Study Group comments on the scope for oncology drug development in Korea, and the issues resulting from the structure of Korea’s healthcare…
Quegen Biotech is a company focusing on manufacturing beta-glucan for use in a range of healthcare products, from hangover cures to oncology treatments. In this interview, Dr Jong Dae Lee…
Pil Soo Oh has been the managing director of Lundbeck Korea since the establishment of the affiliate in 2002. Mr Oh offers his insights into Lundbeck’s footprint in Korea, their…
Jong-Gu Chung, general manager of CooperVision Korea, lifts the lid on his strategy to establish their position in the Korean market for contact lenses. Chung also gives his assessment of…
Established in 1986, the KDRA is Korea’s leading new drug research and development special corporation, established under the Ministry of Science and ICT and composed of 350 members. Its executive…
See our Cookie Privacy Policy Here
